THALIDOMIDE AND LOVASTATIN AS A SALVAGE IMMUNOMODULATORY THERAPY IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

被引：0
|
作者：
Hus, M.
Adamczyk-Cioch, M. [1 ]
Jawniak, D. [1 ]
Grzasko, N. [1 ]
Morawska, M. [1 ]
Kozicka, J. [1 ]
Szostek, M. [2 ]
Helbig, G. [3 ]
机构：
[1] Med Univ, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland
[2] Jagiellonian Univ, Coll Med, Dept Haematol, Krakow, Poland
[3] Silesian Med Univ, Katowice, Poland
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1445
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [31] Therapy of patients with relapsed Multiple Myeloma
    Gramatzki, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 26 - 26
  • [32] SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Castelli, R.
    Pantaleo, G.
    Gallipoli, P.
    Arquati, M.
    Wu, M. A.
    Deliliers, G. Lambertenghi
    Cicardi, M.
    HAEMATOLOGICA, 2015, 100 : 740 - 740
  • [33] Velcade (Vel), Doxil® (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM).
    Chanan-Khan, AA
    Miller, K
    Srinivasan, S
    David, S
    McCarthy, P
    Alam, A
    Bernstein, ZP
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 389B - 389B
  • [34] Outcomes of VDPACE with an Immunomodulatory Agent (IMiD) as a Salvage Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)
    Abdallah, Al-Ola
    Atrash, Shebli
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Ganguly, Siddhartha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S302 - S303
  • [35] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [36] OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma
    Kropff, Martin
    Baylon, Honorata Giongco
    Hillengass, Jens
    Robak, Tadeusz
    Hajek, Roman
    Liebisch, Peter
    Goranov, Stefan
    Hulin, Cyrille
    Blade, Joan
    Caravita, Tomaso
    Avet-Loiseau, Herve
    Moehler, Thomas M.
    Pattou, Claire
    Lucy, Lela
    Kueenburg, Elisabeth
    Glasmacher, Axel
    Zerbib, Robert
    Facon, Thierry
    BLOOD, 2009, 114 (22) : 396 - 396
  • [37] Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT
    Ahmad, I
    Islam, T
    Chanan-Khan, A
    Hahn, T
    Wentling, D
    Becker, JL
    McCarthy, PL
    Alam, AR
    BONE MARROW TRANSPLANTATION, 2002, 29 (07) : 577 - 580
  • [38] KD-PACE salvage therapy for aggressive relapsed multiple myeloma
    Harrell, Shelton
    Khan, Muhammad
    Dhakal, Binod
    Parameswaran, Hari
    Cornell, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E252 - E253
  • [39] Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
    Zemanova, M.
    Scudla, V.
    Adam, Z.
    Gregora, E.
    Pour, L.
    Minarik, J.
    Pavlicek, P.
    Pika, T.
    Bacovsky, J.
    NEOPLASMA, 2008, 55 (04) : 345 - 349
  • [40] Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM).
    Rajkumar, SV
    Dispenzieri, A
    Lacy, M
    Geyer, S
    Iturria, N
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, R
    Greipp, PR
    Gertz, MA
    Witzig, TE
    BLOOD, 2001, 98 (11) : 162A - 163A
12345